From the Department of Pulmonary Medicine (Drs Zuur-Telgen, Brusse-Keizer, VanderValk, and van der Palen) and the Department of Internal Medicine (Dr Zuur-Telgen), Medisch Spectrum Twente; Regional Laboratory of Public Health (Dr Hendrix) and the Department of Research Methodology, Measurement, and Data Analysis (Dr van der Palen), University of Twente; the Department of Pulmonary Medicine (Dr Kerstjens) and the Department of Medical Microbiology (Dr Hendrix), University Medical Centre Groningen, University of Groningen; and Groningen Research Institute for Asthma and COPD (GRIAC) (Dr Kerstjens).
CORRESPONDENCE TO: Maaike C. Zuur-Telgen, MD, Department of Pulmonary Medicine, Medisch Spectrum Twente, PO Box 50 000, 7500 KA Enschede, The Netherlands; e-mail: firstname.lastname@example.org
FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.
We would like to respond to the letter in which Mr Khorfan remarks that several steps are required before proadrenomedullin (proADM) can be accepted as a strong predictor of mortality in COPD. Indeed, as he suggests, before the cutoff value of proADM that was observed in our study can be used in clinical practice it needs to be validated. We already started the validation study in the Cohort of Mortality and Inflammation in COPD (COMIC). The determination of the cutoff has also been done in the COMIC study, but this was performed in only a subset of patients for whom a paired blood sample (in stable state and at hospitalization for an acute exacerbation of COPD) was available.1 In this validation study we obtained 490 blood samples in stable state and 101 blood samples at hospitalization for an acute exacerbation of COPD from 545 patients that did not participate in the already published analysis. In addition, we are validating the cutoff values as suggested by Stolz et al.2,3
We agree with Mr Khorfan that it would be interesting to analyze the incremental value of proADM to current multidimensional indexes for prediction of mortality in COPD, such as the BMI, airflow obstruction, dyspnea, and exercise capacity (BODE) index as he suggests. We hypothesize that proADM has additional value because it could reflect the systemic component of COPD, which is currently not sufficiently done in indexes such as the BODE. Stolz et al3 already showed that proADM plus BODE predicts mortality more accurately than BODE alone. We are currently completing the analyses on the incremental value of proADM to currently used indexes in a pooled assessment of two large European, prospective, observational cohort studies of patients with COPD in stable state. We believe that these additional steps will bring the use of proADM in the clinic even closer to implementation.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.